Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial by Hoever, P. et al.
CliniCal pharmaCology & TherapeuTiCs | VOLUME 91 NUMBER 6 | JUNE 2012 975
CliniC al Trialsnature publishing group
The orexin system has been implicated in the regulation of 
functions such as reward seeking,1 feeding behavior,2 locomo-
tion and physical activity,3–5 and arousal from sleep and the 
sleep–wake cycle.6,7 Orexin-A and orexin-B (also known as 
hypocretin-1 and hypocretin-2, respectively) are neuropep-
tides that bind to the G protein–coupled receptors orexin-1 and 
orexin-2.8–10 In rats as well as in humans, orexin levels in cer-
ebrospinal fluid have been shown to fluctuate with the circadian 
cycle.11–13 The levels are highest at the end of the wake-active 
period and lowest at the end of the sleep period.11–13 Orexin 
deficiency has been linked to narcoleptic symptoms such as 
sudden sleep attacks and cataplexy, in animals14–16 as well as 
in humans.17,18
Experiments in mice and rats have shown that orexin recep-
tor antagonists have sleep-enabling effects.3,19 The dual orexin 
receptor antagonist almorexant elicits somnolence without 
cataplexy in healthy rats, dogs, and humans when given dur-
ing the active phase of the circadian cycle.20 A phase I study 
investigating single-dose daytime administration of almorex-
ant in healthy human subjects showed dose-dependent phar-
macodynamic effects, with reductions in vigilance, alertness, 
visuomotor, and motor coordination observed for the 400- and 
1,000-mg doses.21 In the same study, pharmacoelectroencepha-
lography profiles showed that almorexant decreases alpha Pz–Oz 
and increases beta Fz–Cz activities, as well as delta and theta 
power.21 The increase in delta and theta power may potentially 
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The orexin system is a key regulator of sleep and wakefulness. in a multicenter, double-blind, randomized, placebo-
controlled, two-way crossover study, 161 primary insomnia patients received either the dual orexin receptor antagonist 
almorexant, at 400, 200, 100, or 50 mg in consecutive stages, or placebo on treatment nights at 1-week intervals. The 
primary end point was sleep efficiency (se) measured by polysomnography; secondary end points were objective latency 
to persistent sleep (lps), wake after sleep onset (Waso), safety, and tolerability. Dose-dependent almorexant effects 
were observed on se, lps, and Waso. se improved significantly after almorexant 400 mg vs. placebo (mean treatment 
effect 14.4%; P < 0.001). lps (–18 min (P = 0.02)) and Waso (–54 min (P < 0.001)) decreased significantly at 400 mg vs. 
placebo. adverse-event incidence was dose-related. almorexant consistently and dose-dependently improved sleep 
variables. The orexin system may offer a new treatment approach for primary insomnia.
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indicate slow-wave sleep. Hence, inhibiting the orexin system 
with almorexant could represent a novel approach to the treat-
ment of insomnia.
Insomnia is a persistent problem in ~10% of adults,22–24 
with primary insomnia estimated to be present in ~25% of 
patients with chronic insomnia.25 Sleep-maintenance prob-
lems and nocturnal awakenings are more prevalent than 
sleep-onset difficulties.26,27 Nonpharmacologic treatments 
are often preferred;28 however, eventually, most patients 
either seek pharmacologic treatment or remain untreated.29 
Current standard pharmacologic treatments for insomnia 
include the benzodiazepine receptor agonists, (which poten-
tiate the activity of γ-aminobutyric acid at the ionotropic 
γ-aminobutyric acid-A receptor), and the melatonin receptor 
agonist ramelteon. Benzodiazepine receptor agonists include 
benzodiazepines that decrease sleep latency and increase 
sleep time,30–32 with some agents also improving sleep 
maintenance.30,32 However, benzodiazepines have been asso-
ciated with daytime drowsiness, tolerance, dependency, and 
withdrawal symptoms.33–35 Newer benzodiazepine receptor 
agonists (nonbenzodiazepines) and ramelteon decrease sleep 
latency,33,36,37 whereas some agents, such as eszopiclone and 
modified-release zolpidem, increase sleep time and improve 
sleep maintenance.38,39 The side-effect profiles of nonbenzodi-
azepines and ramelteon appear to be better than those of ben-
zodiazepines, with fewer next-day effects observed.33,35–37,40 
New insomnia therapies with different mechanisms of action 
are currently under investigation with the aim of further 
improving tolerability and sleep maintenance and specifically 
targeting sleep–wake architecture.41,42
We performed a two-part clinical study to evaluate the effect 
of almorexant on sleep in patients with primary insomnia. The 
primary objective was to determine the minimum dose of almo-
rexant that would have a significant effect on sleep efficiency 
(SE). In the first part of the study, the effect of almorexant on SE 
was evaluated at a high dose of 400 mg; thereafter, we conducted 
the dose-ranging part of the study, which aimed to identify the 
minimum effective dose. The safety and tolerability of almorex-
ant and its effect on objective and subjective sleep variables were 
also evaluated.
Results
Between May 2006 and August 2007, 368 patients were screened 
and 161 were enrolled. Supplementary Figure S1 online shows 
a summary of study enrollment and the patients treated at each 
dose level. The main reasons for screening failure were total 
sleep time (TST) >6 h and/or latency to persistent sleep (LPS) 
<20 min. Overall, eight patients were excluded from the per-
protocol analysis: two of these did not complete the second 
treatment night because of adverse events (AEs) and six were 
excluded because of technical difficulties during polysomnog-
raphy. The per-protocol analysis set therefore consisted of 153 
patients. The mean age of all the patients treated was 45.2 years 
(60% in the age group 41–60 years); 66.5% were women; 98.8% 
were Caucasian, 0.6% were Hispanic, and 0.6% were Asian. The 
mean body mass index was 24.2 kg/m2.
efficacy
Objective polysomnographic assessments. The mean values for 
objective sleep variables on the screening/adaptation night 
and the almorexant and placebo treatment nights for almo-
rexant 400, 200, 100, and 50 mg are reported in Table 1. SE 
significantly improved after a single 400-mg dose of almo-
rexant, relative to placebo (mean treatment effect 14.4%; P < 
0.001), thereby demonstrating the efficacy of almorexant at 
this dose level (Figure 1a). A dose-related increase in SE was 
observed with almorexant 100, 200, and 400 mg relative to pla-
cebo (Figure 1a). The lowest effective dose was 100 mg (mean 
treatment effect 4.6%; P = 0.02). No significant treatment effect 
was observed for a dose of 50 mg (mean treatment effect 3.3%; 
P = 0.23), and enrollment was stopped in accordance with the 
study protocol. As a result, only six patients were recruited to 
the 25-mg dose group, and consequently the efficacy data for 
this dose group are not reported; however, the data for these 
patients were included in the safety analysis. The robustness 
of the main analysis was confirmed by similar findings for the 
all-treated analysis, which persisted even after adjustment for 
period and carryover effects (see Supplementary Table S1 
online). LPS was significantly reduced after the 400-mg dose of 
almorexant relative to placebo (mean treatment effect –18 min; 
P = 0.02; Figure 1b). Wake after sleep onset (WASO) declined 
significantly in response to the 400-mg dose relative to placebo 
(mean treatment effect –54 min; P < 0.001), and dose-related, 
clinically relevant, and nominally significant improvements 
were observed after almorexant doses of 200 (P < 0.001) and 
100 mg (P = 0.004) (Figure 1c).
Exploratory polysomnography measurements showed dose-
related increases in mean TST for almorexant 400, 200, and 
100 mg as compared with placebo (Figure 1d). Almorexant 
400 mg was associated with a mean of 411.8 min sleep vs. 
342.1 min with placebo. Higher almorexant doses reduced 
latencies to S1 (400 mg), S2, S3, and S4 sleep stages (200 mg) 
(data not shown). Latency to rapid eye movement (REM) sleep 
decreased dose-dependently (Figure 1e). Almorexant 400 mg 
decreased the time spent in S1 and increased the time spent 
in S2, S3, S4, and REM sleep stages, as compared with placebo 
(Table 2). Similar but less pronounced effects were observed 
after the 200- and 100-mg doses. The percentage of TST spent 
in S1 decreased dose-dependently and the percentage of TST 
spent in REM increased dose-dependently after 400 and 200 mg 
as compared with placebo. The percentages of TST spent in S2, 
S3, and S4 were similar after placebo and after almorexant, irre-
spective of the almorexant dose.
Subjective assessments. The mean values for subjective assess-
ments on the night of the screening/adaptation and on the 
nights of almorexant (400-, 200-, 100-, and 50-mg doses) and 
placebo treatments are given in Table 3. Self-reported patient 
assessments showed dose-related increases in subjective SE 
(Figure 2a) and decreases in subjective sleep latency after 
almorexant 400 and 200 mg relative to placebo (Figure 2b). 
No treatment differences were observed for mean subjective 
WASO at any almorexant dose relative to placebo (Figure 2c). 
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Subjective TST increased dose-dependently (Figure 2d). 
Subjective sleep quality improved after almorexant 400 and 
200 mg relative to placebo (Figure 2e). Awakening quality and 
somatic complaint subscores were similar among treatments 
(data not shown).
Next-day performance. Overall, no relevant negative residual 
effects of the previous night’s treatment were observed after 
any of the almorexant doses relative to placebo with respect to 
subjective alertness levels (Bond and Lader visual analog scale; 
Figure 3a). With respect to mean reaction time (Figure 3b), 
there was a small increase after almorexant 400 mg only 
(mean treatment effect 34.7 ms (95% confidence interval 4.9–
64.5 ms)). Almorexant had no effect on the scores in the fine-
motor test (data not shown); in the digit span test, a lower for-
ward score was observed for almorexant 200 mg as compared 
with placebo (mean treatment effect –0.41 (95% confidence 
interval –0.80 to –0.01)) (data not shown).
safety
Overall, a larger proportion of patients reported at least one AE 
after almorexant administration than after placebo (21.9% vs. 
13.8%). Dizziness, nausea, fatigue, headache, and dry mouth 
were the most common AEs reported after almorexant treat-
ment (Table 4). The proportion of patients with one or more AE 
was highest after almorexant 400 mg (40.0%) but was markedly 
lower after doses of 200, 100, and 50 mg (12.8, 17.9, and 13.9%, 
respectively). There was one serious AE (vasovagal syncope after 
placebo treatment) and no deaths. Other than the serious event, 
all AEs were of mild or moderate severity. One patient discontin-
ued the study because of a febrile upper respiratory tract infection 
after receiving almorexant 400 mg (unrelated to study treatment); 
another discontinued because of the aforementioned serious AE. 
No treatment-related changes in laboratory parameters, vital signs, 
or quantitative electrocardiogram variables were observed, nor 
did any electrocardiogram abnormalities develop. No narcolepsy 
or cataplexy events were reported, and no trend or dose relation-
ship was detected by the narcoleptic effects questionnaire.
Discussion
This is the first study to suggest that the orexin system may play 
a role in nocturnal sleep regulation in humans and that orexin 
receptor antagonism results in sleep-enabling effects in patients 
with primary insomnia. It extends and confirms previous pre-
clinical and clinical observations.20,21 In this two-part clini-
cal study in patients with primary insomnia, a significant and 
clinically relevant increase in SE was observed after almorexant 
400 mg, and the lowest effective dose was 100 mg. Almorexant 
400 mg significantly improved sleep initiation as assessed by 
LPS, and at doses ≥100 mg almorexant dose-dependently and 
significantly decreased WASO, a measure of sleep maintenance. 
Almorexant decreased latency to REM sleep in a dose-depend-
ent manner and decreased latencies to S1–S4 sleep stages at 
the higher doses, while increasing TST. The drug reduced the 
time spent in S1 and increased the time spent in REM sleep. 
At all doses ≥100 mg, it had similar effects on the percentages ta
b
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of TST spent in the S1 and REM sleep stages. The increase in 
time spent in REM sleep brought the percentage of TST spent 
in REM to approximately within the normal range, generally 
20–25% in normal young adults43 and decreasing with age to 
18% in men and 19% in women (age range 61–70 years).44 These 
results indicate that the administration of an almorexant dose as 
low as 100 mg caused an increase in the TST during the night, 
mainly by improving sleep maintenance. This dose level admin-
istered in the daytime did not result in detectable impairment 
of vigilance, alertness, or visuomotor and motor coordination 
in healthy subjects.21
Consistent effects were generally observed between objective 
and subjective assessments of sleep variables, particularly with 
respect to SE, TST, and LPS, although differences were apparent 
at the lower almorexant doses. The drug had no effect on sub-
jective WASO at any dose, although objective WASO decreased 
dose-dependently and patients reported improved sleep qual-
ity. This absence of an effect on subjective WASO warrants 
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Figure 1 Treatment effects of almorexant on objective sleep variables. Mean changes relative to placebo with 95% CIs. CI, confidence interval.
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further investigation in future studies using other sleep-diary 
assessments. With respect to all the objective sleep variables, 
improvements were observed in the mean values from the night 
of screening/adaptation to that after placebo treatment. This 
may be due to an improvement in the patients’ comfort with 
the equipment and sleep laboratory procedures.
Two residual effects on next-day performance, namely, 
increased mean reaction time and a lower forward score on 
the digit span test, were detected in association with the higher 
almorexant doses (400 and 200 mg, respectively). Given that 
the major goal for insomnia therapies is to improve sleep 
maintenance without affecting next-day performance, further 
investigation of any potential next-day effects after almorexant 
treatment at the therapeutic dose would be valuable. Of the cur-
rent standard pharmacologic treatments used for sleep mainte-
nance indications, benzodiazepines are associated with next-day 
effects; however, nonbenzodiazepine agents such as eszopiclone 
and controlled-release zolpidem cause minimal or no residual 
daytime effects.35,39,40,45
The safety profile of almorexant was similar to that of placebo 
for the lower doses, and an increase in the incidence of AEs 
was evident only for the 400-mg dose. There was no evidence 
of narcolepsy or cataplexy as seen from AE reporting and the 
narcoleptic effects questionnaire. The decrease in latencies to 
REM after almorexant administration deserves further attention 
and should be studied in larger trials at the therapeutic doses. 
Shortened REM latency could potentially point to narcolepsy-
like changes in sleep architecture or potential direct effects of 
dual orexin receptor antagonists on sleep; alternatively, it could 
indicate REM rebound in individuals susceptible to chronic par-
tial REM deprivation.
The strengths of this study include the trial design, which 
involved the initial administration of a high dose of almorex-
ant followed by decreasing doses in subsequent stages. This 
design allowed the efficacy of almorexant at a high dose to be 
established first before determining the lowest effective dose. 
Limitations of the study include the shortness of the treatment 
duration from which to assess the efficacy, safety, and tolerability 
of almorexant. The sleep-enabling and -maintaining effects and 
long-term safety and tolerability of dual orexin receptor antago-
nist treatment need to be assessed in large, long-term, ran-
domized trials. This step is essential for new insomnia therapies 
because long-term use of current pharmacologic treatments can 
be associated with the development of tolerance and depend-
ence, and with rebound insomnia on their withdrawal.22,46,47 
The clinical development of almorexant was discontinued in 
January 2011 for reasons not related to any of the observations 
in our study.48
In conclusion, in this study, a single dose of the dual orexin 
receptor antagonist almorexant enabled initiation and mainte-
nance of sleep in patients with primary insomnia. Almorexant 
treatment was associated with a dose-dependent improvement 
in SE, strongly suggesting that the endogenous orexin system 
plays an important role in the sleep–wake cycle. Consistent 
improvements were observed in sleep time, initiation, and main-
tenance, and in the patients’ perception of sleep. Small effects 
on next-day performance were observed only after the higher 
almorexant doses. No safety concerns were revealed. Overall, 
table 2 Mean values of time in sleep stages and percentage of each sleep stage of total sleep time for the treatment nights
almorexant dose level
placebo almorexant 400 mg placebo almorexant 200 mg placebo almorexant 100 mg
sleep stage n = 39 n = 38 n = 38
Stage 1
 Time, min (SD) 35.4 (18.0) 29.2 (16.1)a 34.8 (17.1) 28.4 (12.4)a 28.0 (12.2) 24.2 (11.2)a
 Percentage of  TST, % (SD) 10.6 (5.4) 7.1 (4.0)a 10.1 (6.0) 7.5 (4.6)a 7.8 (4.3) 6.3 (3.2)a
Stage 2
 Time, min (SD) 194.3 (53.8) 231.8 (45.8)a 210.4 (57.4) 227.4 (49.3) 209.9 (48.6) 227.9 (49.3)a
 Percentage of  TST, % (SD) 56.6 (9.0) 56.2 (9.2) 57.9 (11.0) 56.7 (10.6) 55.9 (10.3) 57.7 (11.6)
Stage 3
 Time, min (SD) 24.7 (14.3) 33.8 (22.1)a 28.3 (17.1) 30.4 (16.7) 38.4 (25.9) 40.4 (25.2)
 Percentage of  TST, % (SD) 7.3 (4.0) 8.2 (5.2) 8.1 (6.4) 7.3 (3.7) 9.9 (6.2) 10.0 (5.9)
Stage 4
 Time, min (SD) 31.2 (30.4) 37.4 (35.7)a 30.4 (31.2) 36.6 (32.4)a 26.9 (30.1) 28.8 (28.7)
 Percentage of  TST, % (SD) 9.3 (9.0) 9.3 (9.0) 8.0 (7.3) 8.9 (7.6) 7.1 (7.9) 7.0 (6.7)
REM
 Time, min (SD) 56.5 (23.5) 79.6 (27.7)a 59.1 (24.8) 79.5 (26.6)a 72.7 (27.0) 75.9 (24.9)
 Percentage of  TST, % (SD) 16.2 (5.1) 19.2 (5.9)a 15.9 (5.6) 19.7 (5.7)a 19.3 (6.4) 19.0 (5.7)
Data for almorexant 400, 200, and 100 mg doses only shown; no significant differences were observed between the almorexant 50 mg and placebo treatment nights.
REM, rapid eye movement; TST, total sleep time.
aSignificant difference in treatment effect observed between the almorexant and placebo treatment nights (P < 0.05). P-value determined by paired t-test.
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dual orexin receptor antagonism may offer a potential new treat-
ment approach for primary insomnia.
MethoDs
study design. This was a prospective, multicenter, multistage, double-
blind, randomized, placebo-controlled, two-way crossover, single-
dose study involving almorexant in patients with primary insomnia. 
The study was conducted at 20 centers across Europe and Israel (6 in 
Germany; 3 in Austria; 2 each in Finland, Sweden, and Switzerland; 
and 1 each in Denmark, Israel, the Netherlands, Spain, and the United 
Kingdom). The study design incorporated two parts: a first part to 
determine the efficacy of almorexant at a high dose followed by a sec-
ond part with dose-descending stages to establish the minimum effec-
tive dose. In the first part of the study, the patients received a single 
dose of 400 mg oral almorexant and a placebo on different treatment 
nights 1 week apart, in a crossover design. The patients were allocated 
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Figure 2 Treatment effects of almorexant on subjective sleep variables. Mean changes relative to placebo with 95% CIs. CI, confidence interval; SSA, self-rating 
sleep and awakening quality questionnaire.
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in a 1:1 ratio to the two treatment sequences (placebo/almorexant and 
almorexant/placebo) on the first treatment night, using a computer-
generated randomization list. The study treatments were indistinguish-
able with respect to packaging, appearance, and number of capsules 
administered. The duration of the washout period and the timing of 
study drug administration were based on pharmacodynamic and 
pharmacokinetic data from a previous ascending single-dose study of 
almorexant in healthy subjects. Almorexant was rapidly absorbed, with 
a median time to maximum concentration ranging from 0.7 to 2.3 h 
and rapid decreases to ~20% of peak plasma concentrations over the 
course of 8 h after time to maximum concentration.21 The pharmaco-
dynamics of the drug correlated well with the concentration levels and, 
in general, the onset of pharmacodynamic effects was observed within 
1 h after the dose.21
If the primary end point treatment effect was found to be significant 
(P < 0.05), the study continued with the next lower dose (200, 100, 50, 
or 25 mg) in new patients sequentially until the treatment effect was no 
longer statistically significant. When the number of patients success-
fully screened reached the target sample size for a dose level, subsequent 
patients were assigned to the next dose level. Therefore some patients 
entered the next dose level before the outcome for the previous dose 
was known. After study enrollment was completed, all the patients were 
scheduled to complete all periods and assessments. If the primary end 
point was not significant at 400 mg, 1,000 mg was to be tested against 
placebo in new patients. For each dose level, patients underwent a screen-
ing period (up to 4 weeks), first treatment night, 1-week washout period, 
second treatment night, and 28-day post-treatment follow-up. Patients 
were required to complete a daily sleep log for at least 1 week before the 
screening/adaptation night, 1 week before the first treatment night, and 
during the 1-week washout period before the second treatment night. 
The sleep log consisted of a “day questionnaire” and the self-rating sleep 
and awakening quality questionnaire (SSA).49 The “day questionnaire” 
assessed the patient’s daily habits regarding meals, caffeine-containing 
beverages, alcoholic drinks, smoking, nonstudy medication, and naps. 
In addition, information on the patient’s well-being, physical and emo-
tional stress, and expected stressful events was collected. The investigator 
reviewed the sleep log and assessed the patient’s well-being and compli-
ance before each polysomnography recording. Polysomnography was 
performed for 8 h overnight during the screening/adaptation night and 
each treatment night. The purpose of the screening/adaptation night 
was to objectively confirm the subjectively patient-reported pattern of 
sleep disturbances relating to TST and sleep onset latency. The screening/
adaptation night also served to accustom the patient to the sleep labora-
tory, the polysomnography equipment, and the psychometric tests. All 
polysomnography results were analyzed in accordance with the rules of 
Rechtschaffen and Kales, using the validated Somnolyzer 24 × 7 scoring 
tool50–52 and including a structured expert review. Sleep was scored in 
30-s epochs. During treatment nights, a single dose of almorexant or pla-
cebo was administered 30 min before the start of the polysomnography. 
The patients were required to remain at the center the morning following 
the polysomnography until they were free of symptoms possibly related 
to sleep-enabling medication, as judged by the physician responsible.
Patients. Male and female patients 18–65 years of age were eligible for 
inclusion if they had primary insomnia (by the criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition—Text 
Revision) and a history (≥3 months) of subjectively reported usual TST 
of 3–6 h, usual sleep disturbance with a subjective sleep onset latency 
of >30 min, and daytime complaints associated with poor sleep. Other 
inclusion criteria were polysomnographic confirmation of TST of <6 h 
and LPS ≥20 min during the screening/adaptation night; a body mass 
index of 18–30 kg/m2; no clinically relevant abnormalities as shown 
by a 12-lead electrocardiogram and by hematology/biochemistry test 
results; willingness to refrain from central nervous system-active drugs 
for five half-lives of the drug (at least 1 week); and a negative urine test for 
barbiturates, cannabinoids, amphetamines, and cocaine. Psychotropic 
drugs were not permitted, except hypnotics with a short half-life of ≤10 h 
taken ≥48 h before each treatment night; other stable medications were 
allowed. Cytochrome P450 isoenzyme 3A4 inhibitors were not per-
mitted within 1 week before screening. Key exclusion criteria included 
major depressive disorder, severe psychosis, or significant anxiety disor-
der; a score >2 on the symptom assessment questionnaire for diagnosis of 
apnea,53 a raw score ≥50 on the Zung Self-Rating Depression or Anxiety 
Scale;54,55 and restless legs syndrome or insomnia associated with or 
caused by sleep apnea or periodic limb movement disorder, as assessed 
by polysomnography during the screening night (defined as apnea/
hypopnea index >10/h or periodic limb movement arousal index >10/h, 
respectively). Caffeine consumption of >7 U/ day was not permitted on 
a regular basis (one unit of caffeine was defined as one cup of coffee or 
two cups of tea). Pregnancy and lactation were also exclusion criteria. 
Women with childbearing potential were administered urine pregnancy 
tests at predefined time points during the study and were required to use 
a reliable method of contraception during the entire study duration and 
for at least 3 months after intake of the study drug.
study end points. The primary end point was SE as determined by 
polysomnography, where SE (%) = (TST in minutes/total time in bed in 
minutes (fixed to 480 min)) × 100. Secondary end points, determined 
by polysomnography, were LPS (the time in minutes from the start of 
recording to the beginning of the first 20 nonwake epochs) and WASO 
(the time in minutes spent awake after sleep onset until the end of the 
recording, where sleep onset is the time of the first occurrence of three 
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Figure 3 Treatment effects of almorexant on next-day alertness and 
performance (reaction time test). Mean changes relative to placebo with 95% 
CIs. CI, confidence interval; VAS, visual analog scale.
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consecutive epochs in S1 or first occurrence of S2). Exploratory end 
points measured by polysomnography included TST (the amount of 
actual sleep time in minutes in the total sleep period), latency to sleep 
stages (the time in minutes from the start of the polysomnography 
recording to the first occurrence of the respective sleep stage) including 
REM sleep (the time in minutes from sleep onset to the first occurrence 
of REM), and time spent (in minutes) and percentage of TST for each 
of the sleep stages; and subjective measures of SE, sleep latency, WASO, 
TST, and sleep quality, assessed using the SSA. Next-day performance 
and alertness after treatment nights were assessed using the Bond and 
Lader visual analog scale, which assesses 16 subjective feelings;56 fine-
motor testing, reaction time testing;57,58 and both forward and back-
ward digit span testing.59
safety assessments. AEs and serious AEs occurring within 36 h of 
administration of study treatment were recorded, irrespective of 
whether they were considered to be related to the study treatment. Any 
AE that continued for 24 h after the last drug intake was monitored for 
up to 28 days. Clinical laboratory tests, vital signs, 12-lead electrocardi-
ogram, and a subjective narcoleptic effects questionnaire were assessed 
the morning after study drug administration. The narcoleptic effects 
questionnaire was specifically designed for this study; it evaluated 
symptoms of cataplexy and sleep paralysis seen in narcolepsy with a 
series of yes/no questions on muscle relaxation/weakness and dreams.
statistical analysis. This dose-ranging study was powered to detect a 
placebo-corrected mean difference in SE of 6.5%. SE was assumed to 
be normally distributed, with a standard deviation of 9.8%; no period 
or carryover effects were expected. The desired power for each dose 
level (1,000, 400, 200, 100, 50, and 25 mg) was 98%, 98%, 96%, 94%, 
94%, and 94%, requiring 39, 39, 34, 31, 31, and 31 patients, respectively. 
This approach was used to maximize the power for the first dose tested 
(400 mg) and to have ≥80% actual power at the 50 mg dose level. By this 
calculation, a minimum of 78 patients (400 and 1,000 mg dose levels) 
and a maximum of 166 patients (400, 200, 100, 50, and 25 mg dose lev-
els) were required for the study. The null hypothesis of no difference 
between each dose and placebo was tested using a two-sided paired 
t-test on the per-protocol analysis set, and rejected when P < 0.05. If 
the null hypothesis was rejected, secondary end points were to be 
sequentially tested (i.e., first LPS, then WASO) using a two-sided paired 
t-test. Robustness analyses of the primary and secondary end points 
included the Wilcoxon signed-rank test, and analysis of the all-treated 
set using all available data. For the primary end point, carryover and 
period effects were investigated using mixed modeling. If the carryover 
effect was significant (at the α = 0.10 level), statistical analysis of only 
the first period was carried out. Exploratory end points were analyzed 
in the same manner as the main analysis of the primary end point, but 
any statistical inferences had no confirmatory value. Statistical analyses 
were performed using SAS software version 8.2 (SAS Institute, Cary, 
NC). Safety end points were analyzed descriptively.
study oversight. All materials were reviewed and approved by the 
appropriate independent ethics committees before the study began. The 
study was conducted in accordance with the Declaration of Helsinki, 
followed the International Conference on Harmonization Guidelines 
for Good Clinical Practice, and was registered at ClinicalTrials.gov 
(NCT00640848). Written informed consent was obtained from each 
patient before any study procedure and after adequate explanation of 
the aims, methods, objectives, and potential hazards of the study. It was 
made clear to each patient that he or she was completely free to refuse 
to enter the study or to withdraw from it at any time for any reason. 
Data were collected by the investigators and analyzed by the sponsor. 
The authors had access to the data, and they vouch for the accuracy 
and completeness of the data.
suPPleMentARY MAteRiAl is linked to the online version of the paper at 
http://www.nature.com/cpt
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table 4 Adverse events (safety population) occurring at least once in the overall almorexant group or the placebo group (includes 
related and unrelated events)
event
almorexant
placebo (n = 160)50 mg (n = 36) 100 mg (n = 39) 200 mg (n = 39) 400 mg (n = 40) overalla (n = 160)
Patients with at least 
one event, n (%)
5 (13.9)  7 (17.9) 5 (12.8) 16 (40.0) 35 (21.9) 22 (13.8)
Total events, n 8 11 6 42 73 30
Adverse events, n (%)
Dizziness 1 (2.8) 1 (2.6) 1 (2.6) 2 (5.0) 7 (4.4) 0
Nausea 1 (2.8) 1 (2.6) 1 (2.6) 2 (5.0) 7 (4.4) 0
Fatigue 1 (2.8) 0 0 5 (12.5) 6 (3.8) 4 (2.5)
Headache 2 (5.6) 2 (5.1) 0 2 (5.0) 6 (3.8) 4 (2.5)
Dry mouth 0 1 (2.6) 0 4 (10.0) 5 (3.1) 0
Somnolence 0 0 1 (2.6) 3 (7.5) 4 (2.5) 1 (0.6)
Sleep apnea syndrome 0 1 (2.6) 1 (2.6) 1 (2.5) 3 (1.9) 0
Abdominal pain 0 0 0 2 (5.0) 2 (1.3) 0
Abnormal dreams 0 0 0 2 (5.0) 2 (1.3) 0
Cardiac murmur 0 0 0 2 (5.0) 2 (1.3) 0
Diarrhea 1 (2.8) 0 0 1 (2.5) 2 (1.3) 0
Includes patients who were randomized to receive at least one dose of study medication and had at least one postbaseline assessment.
aIncludes six patients who received almorexant 25 mg.
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